相似文献
1
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.
ACS Pharmacol Transl Sci. 2019 Aug 20;2(6):468-484. doi: 10.1021/acsptsci.9b00048. eCollection 2019 Dec 13.
2
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Circulation. 2017 Aug 29;136(9):849-870. doi: 10.1161/CIRCULATIONAHA.117.028136.
3
Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078.
4
Incretin hormones: Their role in health and disease.
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:5-21. doi: 10.1111/dom.13129.
5
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
Clin Sci (Lond). 2011 Aug;121(3):107-17. doi: 10.1042/CS20110006.
6
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24.
7
Liraglutide: can it make a difference in the treatment of type 2 diabetes?
Int J Clin Pract Suppl. 2010 Oct(167):1-3. doi: 10.1111/j.1742-1241.2010.02497.x.
8
Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25.
9
beta-cell failure in diabetes and preservation by clinical treatment.
Endocr Rev. 2007 Apr;28(2):187-218. doi: 10.1210/10.1210/er.2006-0038. Epub 2007 Mar 12.
10
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.
引用本文的文献
1
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects.
Ann Pediatr Endocrinol Metab. 2025 Aug;30(4):165-174. doi: 10.6065/apem.2448320.160. Epub 2025 Aug 31.
2
The Extraordinary Benefit of Nature's Chemistry to Health, Society, and the Economy.
J Nat Prod. 2025 Jun 27;88(6):1541-1548. doi: 10.1021/acs.jnatprod.5c00554. Epub 2025 Jun 12.
3
GLP-1-based therapies for diabetes, obesity and beyond.
Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.
4
Incretin-based therapeutics for the treatment of neurodegenerative diseases.
Nat Metab. 2025 Apr;7(4):679-696. doi: 10.1038/s42255-025-01263-4. Epub 2025 Apr 10.
5
2FA-Platform Generates Dual Fatty Acid-Conjugated GLP-1 Receptor Agonist TE-8105 with Enhanced Diabetes, Obesity, and NASH Efficacy Compared to Semaglutide.
J Med Chem. 2025 Mar 27;68(6):6178-6192. doi: 10.1021/acs.jmedchem.4c02153. Epub 2025 Mar 5.
6
Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan.
J Pharm Policy Pract. 2024 Dec 4;17(1):2432462. doi: 10.1080/20523211.2024.2432462. eCollection 2024.
7
Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist.
J Clin Med. 2024 Oct 20;13(20):6259. doi: 10.3390/jcm13206259.
8
Harnessing gut cells for functional insulin production: Strategies and challenges.
Biotechnol Notes. 2022 Dec 9;4:7-13. doi: 10.1016/j.biotno.2022.11.005. eCollection 2023.
9
Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
Addict Sci Clin Pract. 2024 Jul 27;19(1):56. doi: 10.1186/s13722-024-00481-7.
10
Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo.
Sci Rep. 2024 Jun 14;14(1):13726. doi: 10.1038/s41598-024-64774-2.
本文引用的文献
1
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE and LDLr Mice by a Mechanism That Includes Inflammatory Pathways.
JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857. doi: 10.1016/j.jacbts.2018.09.004. eCollection 2018 Dec.
2
Big data and black-box medical algorithms.
Sci Transl Med. 2018 Dec 12;10(471). doi: 10.1126/scitranslmed.aao5333.
3
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
Sci Transl Med. 2018 Nov 14;10(467). doi: 10.1126/scitranslmed.aar7047.
4
The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications.
Diabetes. 2018 Sep;67(9):1710-1719. doi: 10.2337/dbi18-0008.
5
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment.
Sci Rep. 2018 Jul 9;8(1):10310. doi: 10.1038/s41598-018-28496-6.
6
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease.
Nat Med. 2018 Jul;24(7):931-938. doi: 10.1038/s41591-018-0051-5. Epub 2018 Jun 11.
7
Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.
Sci Rep. 2017 Dec 13;7(1):17490. doi: 10.1038/s41598-017-17718-y.
8
Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization.
Endocrinology. 2018 Feb 1;159(2):665-675. doi: 10.1210/en.2017-00812.
9
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Lancet. 2017 Oct 7;390(10103):1664-1675. doi: 10.1016/S0140-6736(17)31585-4. Epub 2017 Aug 3.
10
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.
JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220.
Zotero 插件